rood blauwe elepsis logo Belegger.nl

Celyad 2023

1.436 Posts
Pagina: «« 1 ... 26 27 28 29 30 ... 72 »» | Laatste | Omlaag ↓
  1. Garre 24 februari 2023 10:04
    Oh zijn ze vrij vandaag? ?? zie ook niks. Ze komen we met nieuws binnenkort, misschien wel leuk , samenwerking of iets,iemand nog nieuws?
  2. TD_01 24 februari 2023 11:00
    Weinig interesse gewoon. Kleine 2k stuks verhandeld. Ik verwacht geen nieuws persoonlijk
  3. Dannyb44 1 maart 2023 07:32
    Letter to Shareholders
    Dear Shareholder,

    2022 has been a crossroad year for Celyad Oncology (the “Company”), with important changes and turning points. Whilst our clinical programs had clear potential, as we pursued clinical development over the years, we systematically discovered more effective ways of furthering our goal to impact cancer with CAR-T cell therapy. Also, Celyad transitioned from autologous to allogeneic approaches, which changed our company dynamic. We faced challenges stemming from insufficient clinical efficacy: our allogeneic program, CYAD-211, as evaluated in the IMMUNICY-1 trial, did not demonstrate sufficient clinical efficacy to be pursued into Phase II studies without changing the treatment scheme or eligibility criteria. In addition, serious adverse events were reported in the KEYNOTE-B79 trial of our lead allogeneic program, CYAD-101, which resulted in a temporary suspension of the trial. Here, as with CYAD-211, we could only pursue the program with a change of the eligibility criteria, which would have resulted in additional delays and costs.

    This stream of events in the first months of 2022 led to the decision by the board of directors to reshape the strategy of the Company, to focus on its core assets, its world class research unit and intellectual property. A re-organization plan was put in place in June, under the leadership of Michel Lussier, who stepped down as chairman of the board and assumed the position of CEO ad interim, succeeding our then-CEO and CFO, Filippo Petti. Hilde Windels, a member of our board since 2017, stepped in as Chair.

    The Company executed an in-depth organizational transformation in the second half of the year:
    Significant cost cutting and cost saving initiatives have been implemented in order to strictly allocate the resources of the Company to the activities and programs that could potentially bring maximum value to shareholders. To that end, Celyad discontinued non-strategic R&D programs and opted not to begin any new clinical trial development;
    A hiring freeze was implemented as of March 2022;
    26 employees and four contractors were transferred in October to Cellistic™ (a division of Ncardia) following the acquisition of Celyad’s Cell Therapy Manufacturing Unit (CTMU) by Ncardia Belgium SA;
    Effective 9 January 2023, the clinical team (eight employees) joined the organization of ProPharma Group Holdings LLC, a global reputed CRO with whom Celyad has simultaneously entered into a service agreement for support relating to the closing of its clinical trials. The clinical trials remain under the Company’s responsibility as sponsor while the clinical workforce has been transferred to said partner to secure a seamless closing of the clinical studies, preserving the best interests of the patients and investigational sites; and
    The Company also sold several assets (e.g. equipment & refurbishment for 1,3Mi€ in order to relocate to a nearby facility, better suited to the Company’s future needs).

    All initiatives undertaken by the Company since spring 2022 have created a projected cash burn reduction that would allow a forecasted cash runway extension by approximately 12 months, up to the fourth quarter of 2023, without any external financing.

    Starting in 2023, Celyad Oncology will now entirely focus on its new business strategy, moving forward with an adapted organization and, we believe, the right headcount to successfully deliver on it.
    On the financing side, in the third quarter of 2022, the Company engaged Van Lanschot Kempen N.V. to evaluate several financing options.
    In summary, while our clinical results have not lived up to expectations, we are hopeful for the many patients who have been successfully treated in these programs and the solid foundation it has created to move these therapies further. We believe that our clinical accomplishments, strengthened with the current and future research efforts, can lead to commercially successful products.
    Having dealt with the 2022 challenges, Celyad has now successfully reinvented itself as a leaner, more agile organization with three clear objectives:
    Strengthen its research focus centered around NKG2D, B7-H6 and shRNA platforms;
    Maximize its valuable IP estate and
    Drive innovation through strategic collaborations.
    We believe that Celyad is well prepared and has the relevant unique assets and know how to create significant shareholder value in the next few years.
    Michel Lussier
    Co-Founder, Interim CEO
    Hilde Windels
    Chair
  4. husa 1 maart 2023 11:18
    zoals het er nu uit ziet en als er enige waarde in hun onderzoeken zit. worden ze zodra er nieuws is overgenomen.
  5. dekeu 1 maart 2023 13:15
    Galapagos richt zijn pijlen nu ook op carT celtherapie. Wie weet nemen zij de know how en het gespecialiseerd personeel over.
  6. Garre 1 maart 2023 15:15
    Ja kwestie van tijd dat het overgenomen wordt dat lijkt me wel een logisch vervolg.
  7. TD_01 1 maart 2023 16:16
    quote:

    Garre schreef op 1 maart 2023 15:15:

    Ja kwestie van tijd dat het overgenomen wordt dat lijkt me wel een logisch vervolg.
    Wil het eerst wel eens zien... en dan de grote vraag wat willen ze ervoor geven....
  8. Garre 1 maart 2023 16:35
    Ach ja ze hebben nog geld tot/met q4 2023.
    En ze hebben dus kempen ingeschakeld..
    Er wordt nu wel weer met de koers gespeeld
  9. Garre 1 maart 2023 16:47
    Zo ineens weer van 1,15 naar 1,04 door 3 verkopers samen a dik 13000 stuks ..
    Raar koersverloop.
  10. @Swing 1 maart 2023 19:01
    quote:

    Garre schreef op 1 maart 2023 16:35:

    Ach ja ze hebben nog geld tot/met q4 2023.
    En ze hebben dus kempen ingeschakeld..
    Er wordt nu wel weer met de koers gespeeld
    Wees er maar zeker van als de tent niet wordt overgenomen een heel stuk vroeger dan Q4 geld zal opgehaald worden.
  11. forum rang 4 Spoorstudent 1 maart 2023 23:22
    Ik acht de kans klein op overname. Mijn menng. Gevoel.
    Galapagos heeft de cash. Zeker. Maar of…
    Grote kans dat voor de zomer Kempen met de pet rond gaat.
  12. TD_01 1 maart 2023 23:39
    quote:

    Spoorstudent schreef op 1 maart 2023 23:22:

    Ik acht de kans klein op overname. Mijn menng. Gevoel.
    Galapagos heeft de cash. Zeker. Maar of…
    Grote kans dat voor de zomer Kempen met de pet rond gaat.
    Ben er ook niet zeker van. Er zijn genoeg biotechaandelen die de rest van hun bestaan over de bodem schuiven...

    Ik geloof dat ze op 23 maart hun full year resultaten 2022 gaan geven maar ook daar moeten we niks spectaculairs verwachten lijkt me
  13. Tests 2 maart 2023 08:44
    Hoewel een overname nooit helemaal valt uit te sluiten, leid ik uit de toonzetting van de brief af dat Celyad met een dergelijk scenario op dit moment in het geheel geen rekening houdt. Een ronde geld ophalen lijkt de volgende 'milestone'.
  14. forum rang 6 trab33 2 maart 2023 13:56
    quote:

    dekeu schreef op 1 maart 2023 13:15:

    Galapagos richt zijn pijlen nu ook op carT celtherapie. Wie weet nemen zij de know how en het gespecialiseerd personeel over.
    gespecialiseerd personeel met een beetje know how is allang weesten solliciteren
1.436 Posts
Pagina: «« 1 ... 26 27 28 29 30 ... 72 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Belegger.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.102
AB InBev 2 5.529
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.948
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.807
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 192
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.781
Aedifica 3 925
Aegon 3.258 323.007
AFC Ajax 538 7.088
Affimed NV 2 6.301
ageas 5.844 109.897
Agfa-Gevaert 14 2.062
Ahold 3.538 74.345
Air France - KLM 1.025 35.249
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.048
Alfen 16 25.103
Allfunds Group 4 1.514
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 409
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.629
AMG 971 134.099
AMS 3 73
Amsterdam Commodities 305 6.740
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 15.031
Apollo Alternative Assets 1 17
Apple 5 384
Arcadis 252 8.789
Arcelor Mittal 2.034 320.895
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.342
Aroundtown SA 1 221
Arrowhead Research 5 9.750
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.564
ASML 1.766 109.546
ASR Nederland 21 4.505
ATAI Life Sciences 1 7
Atenor Group 1 522
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.733
Axsome Therapeutics 1 177
Azelis Group 1 66
Azerion 7 3.438